Table 3. Univariate and multivariate analysis of patientś and tumour characteristics related to DRFS in the validation set 1 (GSE25066).
| n (events) |
Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
|
GSE25066 validation set | |||||
| Age | 0.656 | 0.032 | |||
| ⩽45 | 44 (20) | 1 | |||
| >45 | 69 (35) | 0.656 (0.508–1.532) | |||
| Clinical T stage | 0.006 | ||||
| 0–2 | 52 (18) | 1 | 1 | 0.032 | |
| 3–4 | 61 (37) | 2.172 (1,232–3,831) | 1.878 (1.054–3.346) | ||
| Clinical nodal stage | 0.010 | 0.025 | |||
| 0 | 26 (9) | 1 | 1 | ||
| 1 | 52 (23) | 1.706 (0.785–3.711) | 0.178 | 1.609 (0.740–3.499) | |
| 2–3 | 35 (23) | 3.109 (1.429–6.767) | 0.004 | 2.779 (1.271–6.079) | |
| Clinical AJCC stage | 0.004 | ||||
| I–IIB | 51 (18) | 1 | |||
| IIIA, IIIB, IIIC, Inflammatory | 62 (37) | 2.3 (1,306–4,048) | |||
| Histological grade | 0.542 | ||||
| 2 | 17 (9) | 1 | |||
| 3 | 86 (38) | 0.798 (0.386–1.651) | |||
| Prognostic signature | 0.002 | 0.003 | |||
| Low risk | 57 (20) | 1 | 1 | ||
| High risk | 56 (35) | 2.358 (1.359–4.091) | 2.308 (1.326–4.018) | ||
Abbreviations: CI, confidence interval; HR, hazard ratio. Bold entries denote statistically significant values.